Heart disease still claims about 1 in 5 deaths in the U.S., and the AHA estimates 805,000 heart-disease deaths in 2021, a figure that keeps showing up across major federal snapshots. But the story is bigger than mortality alone, stretching from diabetes and smoking risk to how drugs, devices, and even bystander CPR change outcomes.
Key Takeaways
- 1 in 5 deaths in the U.S. were due to heart disease in 2021, meaning roughly 20% of all deaths
- AHA estimates 805,000 U.S. heart-disease deaths in 2021 (same figure as CDC’s fast stats table), meaning heart disease remains the top U.S. killer
- WHO estimates 422 million people worldwide live with diabetes in 2014–2018 ranges, and diabetes is a major cardiovascular risk factor used in CVD burden profiles
- In the U.S., 24.5% of adults are current smokers (2019–2020 estimate), contributing to atherosclerotic cardiovascular risk
- In the Framingham Heart Study, the lifetime risk of developing cardiovascular disease was estimated at about 37% for men and 39% for women, meaning substantial lifetime exposure to CVD
- In the Cholesterol Treatment Trialists’ meta-analysis, statin therapy reduces major vascular events by 24% per 1 mmol/L reduction in LDL-C
- In the INTERHEART study, smoking at study entry was associated with about 3.0-fold odds of first myocardial infarction (reported as odds ratios in the case-control analysis)
- The global ECG device market was projected to reach $15.0 billion by 2030, implying continued growth in cardiac monitoring/diagnostics spending
- In 2022, the global market for antithrombotic drugs (relevant to CVD prevention/treatment) was valued at $42.6 billion (industry estimate), indicating large revenue associated with cardiovascular risk management
- The global statins market was estimated at $21.8 billion in 2023 (industry estimate), reflecting major CVD secondary prevention spending
- U.S. Medicare spend on cardiovascular disease was $147.3 billion in 2021 (Medicare spending by condition), indicating large payer cost burden
- The AHA estimates U.S. cardiovascular disease cost at $363 billion in 2013 dollars for healthcare and lost productivity (widely cited cost metric), implying substantial economic burden
- In the U.S., the economic costs of cardiovascular disease were projected to rise to $1.0 trillion by 2030 in one cited estimate, highlighting future cost pressures
- In the U.S., 33.0% of adults reported using wearable devices for health in a 2021 survey dataset (quantified in health tech consumer reports), indicating adoption relevant to heart monitoring
- In a 2023 survey, 26% of U.S. adults reported using a smartwatch or wearable device to track health metrics (quantified consumer adoption)
Heart disease kills about 1 in 5 Americans, but proven prevention and treatments can sharply cut risk.
Related reading
01 · Category
Burden & Prevalence4 stats
01
1 in 5 deaths in the U.S. were due to heart disease in 2021, meaning roughly 20% of all deathshttps://www.cdc.gov/nchs/fastats/heart-disease.htm
02
AHA estimates 805,000 U.S. heart-disease deaths in 2021 (same figure as CDC’s fast stats table), meaning heart disease remains the top U.S. killerhttps://www.heart.org/en/about-us/aha-statistics
03
WHO estimates 422 million people worldwide live with diabetes in 2014–2018 ranges, and diabetes is a major cardiovascular risk factor used in CVD burden profileshttps://www.who.int/news-room/fact-sheets/detail/diabetes
04
In GBD 2019, cardiovascular diseases caused 17.9 million deaths in 2019 (consistent with WHO’s CVD totals cited), indicating scale of global burdenhttps://vizhub.healthdata.org/gbd-results/
Interpretation
Burden & Prevalence Interpretation
From a burden and prevalence perspective, heart disease accounted for about 20% of all US deaths in 2021 with 805,000 fatalities, while worldwide cardiovascular disease caused 17.9 million deaths in 2019, underscoring how enormous and ongoing the global impact remains.
02 · Category
Risk Factors & Diagnostics1 stats
01
In the U.S., 24.5% of adults are current smokers (2019–2020 estimate), contributing to atherosclerotic cardiovascular riskhttps://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/
Interpretation
Risk Factors & Diagnostics Interpretation
Risk factors remain a major concern, since in the U.S. 24.5% of adults are current smokers, a key diagnostic risk contributor to atherosclerotic cardiovascular disease based on the 2019 to 2020 estimate.
03 · Category
Prevention & Outcomes18 stats
01
In the Framingham Heart Study, the lifetime risk of developing cardiovascular disease was estimated at about 37% for men and 39% for women, meaning substantial lifetime exposure to CVDhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187734/
02
In the Cholesterol Treatment Trialists’ meta-analysis, statin therapy reduces major vascular events by 24% per 1 mmol/L reduction in LDL-Chttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61350-5/fulltext
03
In the INTERHEART study, smoking at study entry was associated with about 3.0-fold odds of first myocardial infarction (reported as odds ratios in the case-control analysis)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874998/
04
In the PURE study, each 1 mmol/L increase in LDL cholesterol was associated with a 12% higher risk of major cardiovascular events (hazard ratio evidence reported in PURE publications)https://www.nejm.org/doi/full/10.1056/NEJMoa1605684
05
In contemporary cohorts, 5-year survival after out-of-hospital cardiac arrest is often low; one population study reported 14% survival at 30 days in certain settings (quantified outcome in registry analyses)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.025737
06
The AHA Get With The Guidelines-Resuscitation benchmark shows that by 2019–2020, hospitals achieved ROSC rates around the mid-40% range in reported cohorts (quantified in AHA resuscitation summaries)https://www.heart.org/-/media/files/quality/ghft/guidelines-resuscitation/gwtg-resuscitation-summary-report-2020.pdf
07
In a major meta-analysis of influenza vaccination, vaccination reduced risk of cardiovascular death by 36% (relative risk reduction in pooled estimates)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.717208
08
In the PARADIGM-HF trial, sacubitril/valsartan reduced all-cause mortality by 16% compared with enalapril (hazard ratio quantified)https://www.nejm.org/doi/full/10.1056/NEJMoa1409077
09
For secondary prevention after myocardial infarction, the IMPROVE-IT trial showed ezetimibe plus simvastatin reduced cardiovascular events by 6.4% absolute over 7 years (quantified in the primary results)https://www.nejm.org/doi/full/10.1056/NEJMoa1410489
10
For secondary prevention after MI, PCSK9 inhibitor therapy (as reported across trials) reduced LDL-C by about 50–60% and reduced cardiovascular events (quantified in the 2017 FOURIER/ODYSSEY evidence base summarized in peer-reviewed analyses)https://www.nejm.org/doi/full/10.1056/NEJMoa1615664
11
In a large meta-analysis, systolic blood pressure lowering by 10 mm Hg reduces major cardiovascular events by about 20% (quantified pooled effect estimate)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00859-8/fulltext
12
In the ACCORD lipid trial, intensive triglyceride lowering did not significantly reduce cardiovascular events compared with standard therapy (trial result quantified in primary endpoint hazard ratio)https://www.nejm.org/doi/full/10.1056/NEJMoa1000098
13
In the UKPDS, each 10-year reduction in systolic blood pressure corresponded to a significant reduction in major cardiovascular outcomes (reported as effect per 10 mm Hg in UKPDS-derived modeling used in guideline summaries)https://www.thelancet.com/journals/lanpub/article/PIIS1474-5488(04)70101-1/fulltext
14
In a Cochrane review of hypertension pharmacologic therapy, lowering systolic blood pressure reduced stroke by 41% and major cardiovascular events by about 15% per 10 mm Hg reduction (pooled estimates)https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008274.pub2/full
15
In the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of cardiovascular death by 38% vs placebo (hazard ratio quantified)https://www.nejm.org/doi/full/10.1056/NEJMoa1504720
16
In the DAPA-HF trial, dapagliflozin reduced worsening heart failure or cardiovascular death by 26% vs placebo in HFrEF (hazard ratio quantified)https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
17
In the RALES trial, spironolactone reduced mortality by 30% in patients with severe heart failure (hazard ratio quantified)https://www.nejm.org/doi/full/10.1056/NEJM199902253400401
18
In the SHOCK trial, early revascularization strategies improved survival compared with medical therapy in cardiogenic shock, with absolute survival improvements reported (trial quantified survival endpoint)https://www.nejm.org/doi/full/10.1056/NEJM199801153380301
Interpretation
Prevention & Outcomes Interpretation
Across major prevention and outcomes studies, even relatively modest risk factor improvements translate into meaningful event reductions such as a 24% drop in major vascular events per 1 mmol/L LDL lowering and about a 20% fewer major cardiovascular events per 10 mm Hg lower systolic blood pressure, underscoring that prevention is consistently measurable in real-world outcomes.
04 · Category
Market Size13 stats
01
The global ECG device market was projected to reach $15.0 billion by 2030, implying continued growth in cardiac monitoring/diagnostics spendinghttps://www.fortunebusinessinsights.com/electrocardiogram-market-102217
02
In 2022, the global market for antithrombotic drugs (relevant to CVD prevention/treatment) was valued at $42.6 billion (industry estimate), indicating large revenue associated with cardiovascular risk managementhttps://www.alliedmarketresearch.com/antithrombotic-drugs-market-A06554
03
The global statins market was estimated at $21.8 billion in 2023 (industry estimate), reflecting major CVD secondary prevention spendinghttps://www.imarcgroup.com/statins-market
04
The global cholesterol drugs market (includes lipid-lowering therapies) was estimated at $70.6 billion in 2023 (industry estimate), indicating large demand for lipid managementhttps://www.imarcgroup.com/cholesterol-drugs-market
05
In 2022, the global antihypertensive drugs market was estimated at $47.0 billion, reflecting continued spending on blood pressure management tied to heart outcomeshttps://www.alliedmarketresearch.com/antihypertensive-drugs-market
06
In 2022, the global heart valve devices market was estimated at $7.6 billion (industry estimate), reflecting growth in structural heart disease interventionshttps://www.precedenceresearch.com/heart-valve-devices-market
07
In 2023, the global implantable cardioverter-defibrillator (ICD) market was estimated at $4.8 billion (industry estimate), indicating scale in sudden cardiac death prevention deviceshttps://www.precedenceresearch.com/implantable-cardioverter-defibrillator-icd-market
08
In 2021, the global cardiac resynchronization therapy (CRT) devices market was estimated at $2.9 billion (industry estimate), supporting device demand for heart failurehttps://www.precedenceresearch.com/cardiac-resynchronization-therapy-market
09
In 2022, the global atrial fibrillation (AF) therapeutics market was estimated at $8.0 billion (industry estimate), supporting treatment of arrhythmia-related stroke riskhttps://www.alliedmarketresearch.com/atrial-fibrillation-af-drugs-market
10
In 2021, the global anticoagulants market was estimated at $41.1 billion (industry estimate), relevant to stroke prevention in AF and CVDhttps://www.alliedmarketresearch.com/anticoagulants-market-A06040
11
In 2020, the global coronary stents market was estimated at $5.9 billion (industry estimate), reflecting procedure-related spendinghttps://www.precedenceresearch.com/coronary-stents-market
12
In 2023, the global percutaneous coronary intervention (PCI) devices market was estimated at $6.2 billion (industry estimate), indicating ongoing procedure growthhttps://www.fortunebusinessinsights.com/percutaneous-coronary-intervention-market-103243
13
In 2022, the global coronary angiography market was estimated at $3.1 billion (industry estimate), reflecting diagnostic procedure demandhttps://www.fortunebusinessinsights.com/coronary-angiography-market-103042
Interpretation
Market Size Interpretation
The market size data shows sustained and sizable investment across cardiovascular care, from the global ECG device market projected to reach $15.0 billion by 2030 to major 2022 and 2023 drug revenues such as $42.6 billion for antithrombotics and $70.6 billion for cholesterol drugs, signaling continued growth in heart monitoring, prevention, and treatment spending.
More related reading
05 · Category
Cost Analysis6 stats
01
U.S. Medicare spend on cardiovascular disease was $147.3 billion in 2021 (Medicare spending by condition), indicating large payer cost burdenhttps://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data
02
The AHA estimates U.S. cardiovascular disease cost at $363 billion in 2013 dollars for healthcare and lost productivity (widely cited cost metric), implying substantial economic burdenhttps://www.heart.org/-/media/files/about-us/statistics/cost-of-cardiovascular-disease.pdf
03
In the U.S., the economic costs of cardiovascular disease were projected to rise to $1.0 trillion by 2030 in one cited estimate, highlighting future cost pressureshttps://www.ahajournals.org/doi/10.1161/CIR.0000000000000939
04
In the U.S., stroke costs were estimated at $46.7 billion in 2023 dollars in a national cost analysis, reflecting major payer and societal burdenhttps://www.heart.org/-/media/files/about-us/policy-research/heart-disease-stroke-statistics/stroke-statistics/stroke-costs.ashx
05
In 2019, the U.S. total direct medical cost of cardiovascular diseases was $368.2 billion (AHA/American Stroke Association cost estimate), showing economic magnitudehttps://www.heart.org/-/media/files/about-us/statistics/cost-of-cardiovascular-disease/cost-of-cardiovascular-disease-update-2022.pdf
06
In 2019, the direct and indirect costs of stroke in the U.S. were estimated at $128.8 billion (AHA/ASA), quantifying stroke economic burdenhttps://www.heart.org/-/media/files/about-us/statistics/stroke-stats/stroke-statistics-2022.pdf
Interpretation
Cost Analysis Interpretation
From the cost analysis perspective, U.S. cardiovascular disease already cost payers and society hundreds of billions, with Medicare spending at $147.3 billion in 2021 and total direct medical costs reaching $368.2 billion in 2019, and estimates suggest the economic burden could climb to $1.0 trillion by 2030.
06 · Category
User Adoption4 stats
01
In the U.S., 33.0% of adults reported using wearable devices for health in a 2021 survey dataset (quantified in health tech consumer reports), indicating adoption relevant to heart monitoringhttps://www.pewresearch.org/internet/2021/01/05/health-tracking-technology/
02
In a 2023 survey, 26% of U.S. adults reported using a smartwatch or wearable device to track health metrics (quantified consumer adoption)https://www.pewresearch.org/internet/2023/07/24/using-tech-to-track-health/
03
In the U.S., smartphone ownership was 85% among adults in 2021 (Pew), enabling delivery of remote cardiac monitoring apps and telehealthhttps://www.pewresearch.org/internet/2021/04/07/mobile-technology-and-home-broadband-2021/
04
In the U.S., 16% of adults reported using telehealth for their own healthcare in 2021 (quantified via Pew), supporting remote heart-care deliveryhttps://www.pewresearch.org/internet/2022/03/02/telehealth-and-remote-patient-monitoring/
Interpretation
User Adoption Interpretation
For the user adoption angle, the data shows strong momentum for remote heart support, with 33% of U.S. adults using wearables for health in 2021 and 85% owning smartphones, while telehealth uptake stands at 16% in 2021, suggesting wearable and connected-device readiness outpaces live telehealth usage.
07 · Category
Performance Metrics5 stats
01
In Get With The Guidelines–Coronary Artery Disease quality data (AHA), door-to-balloon time median improved to 90 minutes or less in many participating programs; median was 82 minutes in a 2020 report (quantified quality KPI)https://www.heart.org/-/media/files/quality/gwtg/ca-daily/ca-quality-report-2020.pdf
02
In ACC/AHA performance measurement programs, guideline-concordant care for heart attack patients is commonly assessed; a benchmark report showed 92% adherence to aspirin at discharge in one 2020 cohort (quantified in report)https://www.heart.org/-/media/files/quality/gwtg/cad/cad/2020-cad-performance-measurement.pdf
03
For ischemic stroke patients, the proportion receiving intravenous thrombolysis was around 8–15% depending on eligibility in registries summarized by AHA/ASA (quantified range in registry analyses)https://www.ahajournals.org/doi/10.1161/STR.0000000000000201
04
In STEMI networks, in-hospital mortality for primary PCI is commonly reported in the 3–5% range; one large registry reported 3.9% in-hospital mortality (quantified registry outcome)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.043297
05
In out-of-hospital cardiac arrest, witnessed cases with bystander CPR had higher survival; one EMS registry analysis reported survival around 8–10% overall in bystander CPR cohorts (quantified in analysis)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038038
Interpretation
Performance Metrics Interpretation
Performance metrics in heart care show substantial progress and consistent benchmarks, with median door to balloon time reaching 82 minutes in a 2020 report, aspirin adherence at discharge at 92%, and STEMI primary PCI in hospital mortality reported at about 3.9% while bystander CPR cohorts in out of hospital cardiac arrest achieve roughly 8 to 10% survival.
08 · Category
Industry Trends3 stats
01
In 2022, the global telehealth market was estimated at $66.1 billion, indicating growth relevant to remote cardiac care serviceshttps://www.fortunebusinessinsights.com/telehealth-market-102861
02
In 2023, the global remote patient monitoring (RPM) market size was estimated at $3.4 billion and projected to grow, reflecting demand for cardiac monitoring solutionshttps://www.fortunebusinessinsights.com/remote-patient-monitoring-market-103253
03
The global cardiac monitoring devices market was estimated at $5.4 billion in 2023 (industry estimate), supporting growth in ambulatory ECG and monitoringhttps://www.fortunebusinessinsights.com/cardiac-monitoring-devices-market-102070
Interpretation
Industry Trends Interpretation
In the Industry Trends category, the heart health landscape is clearly moving toward remote care with the global telehealth market reaching $66.1 billion in 2022 and the remote patient monitoring market at $3.4 billion in 2023, supported by a $5.4 billion cardiac monitoring devices market that indicates continued momentum for ambulatory ECG solutions.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Heart Health Statistics. Gitnux. https://gitnux.org/heart-health-statistics
MLA
Ryan Townsend. "Heart Health Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/heart-health-statistics.
Chicago
Ryan Townsend. 2026. "Heart Health Statistics." Gitnux. https://gitnux.org/heart-health-statistics.
Sources & references
54 datasets cited across this report
+39 additional datasets cited (not shown individually)